{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:04:17Z","timestamp":1770469457438,"version":"3.49.0"},"reference-count":86,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    <jats:italic>Chlamydia trachomatis<\/jats:italic>\n                    and\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    were the most common bacteria causing sexually transmitted infections (STIs) in 2020, with 211 million cases worldwide. Despite the fact that the co-infections of\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    with\n                    <jats:italic>C. trachomatis<\/jats:italic>\n                    are common, there is no single treatment effective against both pathogens. Ceftriaxone, the current recommended drug for gonococcal infections\n                    <jats:italic>,<\/jats:italic>\n                    is not effective against\n                    <jats:italic>C. trachomatis<\/jats:italic>\n                    . Additionally,\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    has developed resistance against the drugs recommended for treating chlamydial infections. Therefore, new drugs capable of treating\n                    <jats:italic>C. trachomatis<\/jats:italic>\n                    \/\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    co-infections are needed. Drug repurposing is an attractive, fast-track approach for antimicrobial drug discovery. In an attempt to address the unmet need for development of\n                    <jats:italic>C. trachomatis<\/jats:italic>\n                    \/\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    therapeutics utilizing the drug repurposing approach, we screened the antibacterial compounds library against\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    . This library encompasses a unique collection of 1,128 bioactive compounds with validated antibacterial activities\n                    <jats:italic>.<\/jats:italic>\n                    A total of 172 active hits were identified, and then repeated drugs with different salts or previously reported drugs were excluded before determining the minimum inhibitory concentrations (MICs) against\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    FA1090. Thereafter, the anti-\n                    <jats:italic>C. trachomatis<\/jats:italic>\n                    activities of the 14 selected drugs were assessed. We identified gloxazone and SPR719 as promising agents with potent activities against both\n                    <jats:italic>C. trachomatis<\/jats:italic>\n                    and\n                    <jats:italic>N. gonorrhoeae<\/jats:italic>\n                    (MICs\u2009\u2264\u20091 \u00b5M)\n                    <jats:italic>.<\/jats:italic>\n                    Collectively\n                    <jats:italic>,<\/jats:italic>\n                    SPR719 and gloxazone could be considered promising agents warranting further investigation to address the unmet need in the treatment of bacterial STIs.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0340486","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:22:19Z","timestamp":1770402139000},"page":"e0340486","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening a library of antibacterial compounds leads to discovery of novel inhibitors for Neisseria gonorrhoeae and Chlamydia trachomatis"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2902-3551","authenticated-orcid":true,"given":"Abdallah S.","family":"Abdelsattar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader S.","family":"Abutaleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-0458","authenticated-orcid":true,"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"3","key":"pone.0340486.ref001","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0049-0172(81)80002-9","article-title":"Disseminated gonococcal infection (DGI) and gonococcal arthritis (GCA): II. Clinical manifestations, diagnosis, complications, treatment, and prevention","volume":"10","author":"AT Masi","year":"1981","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"pone.0340486.ref002","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ajem.2011.07.014","article-title":"Laboratory-confirmed gonorrhea and\/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis","volume":"30","author":"AM Burnett","year":"2012","journal-title":"Am J Emerg Med"},{"issue":"7","key":"pone.0340486.ref003","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"JS Jensen","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"pone.0340486.ref004","unstructured":"Emergence of multi-drug resistant Neisseria gonorrhoeae - threat of global rise in untreatable sexually transmitted infections fact sheet. [Cited 2025 June 7]. https:\/\/www.who.int\/publications\/i\/item\/emergence-of-multi-drug-resistant-neisseria-gonorrhoeae---threat-of-global-rise-in-untreatable-sexually-transmitted-infections-fact-sheet"},{"issue":"6","key":"pone.0340486.ref005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.olq.0000240344.20665.63","article-title":"Pelvic examination findings and Chlamydia trachomatis infection in asymptomatic young women screened with a nucleic acid amplification test","volume":"34","author":"WM Geisler","year":"2007","journal-title":"Sex Transm Dis"},{"key":"pone.0340486.ref006","unstructured":"Sexually transmitted infections (STIs). [Cited 2025 June 7]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis)"},{"key":"pone.0340486.ref007","unstructured":"Gonorrhoea (Neisseria gonorrhoeae infection). [Cited 2024 August 14]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/gonorrhoea-(neisseria-gonorrhoeae-infection)"},{"key":"pone.0340486.ref008","unstructured":"Chlamydia. [cited 19 May 2025]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chlamydia"},{"issue":"6","key":"pone.0340486.ref009","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bpobgyn.2006.06.003","article-title":"A review on infection with Chlamydia trachomatis","volume":"20","author":"K Manavi","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"pone.0340486.ref010","first-page":"30","article-title":"Chlamydia trachomatis infection: screening and management","volume":"21","author":"MB Keegan","year":"2014","journal-title":"J Clin Outcomes Manag"},{"issue":"7","key":"pone.0340486.ref011","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/jcp.2003.015628","article-title":"Gonococcal endocarditis: a rare complication of a common disease","volume":"57","author":"A Shetty","year":"2004","journal-title":"J Clin Pathol"},{"issue":"5","key":"pone.0340486.ref012","doi-asserted-by":"crossref","first-page":"101629","DOI":"10.1016\/j.cpcardiol.2023.101629","article-title":"Sexually transmitted infections & the heart","volume":"48","author":"K Liblik","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"pone.0340486.ref013","article-title":"A case of purulent gonococcal arthritis","volume":"19","author":"MM Vidaurrazaga","year":"2019","journal-title":"IDCases"},{"issue":"49","key":"pone.0340486.ref014","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.15585\/mmwr.mm6949a5","article-title":"Notes from the Field: First case in the United States of Neisseria gonorrhoeae Harboring emerging mosaic penA60 Allele, conferring reduced susceptibility to cefixime and ceftriaxone","volume":"69","author":"MA Picker","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0340486.ref015","unstructured":"Gonococcal Infections Among Adolescents and Adults - STI Treatment Guidelines. [Cited 2024 August 14]. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/gonorrhea-adults.htm"},{"issue":"50","key":"pone.0340486.ref016","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","article-title":"Update to CDC\u2019s treatment guidelines for gonococcal infection, 2020","volume":"69","author":"S St Cyr","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"37","key":"pone.0340486.ref017","doi-asserted-by":"crossref","first-page":"2300456","DOI":"10.2807\/1560-7917.ES.2023.28.37.2300456","article-title":"Two cases of extensively drug-resistant (XDR) Neisseria gonorrhoeae infection combining ceftriaxone-resistance and high-level azithromycin resistance, France, November 2022 and May 2023","volume":"28","author":"C Maubaret","year":"2023","journal-title":"Euro Surveill"},{"issue":"24","key":"pone.0340486.ref018","doi-asserted-by":"crossref","first-page":"2200455","DOI":"10.2807\/1560-7917.ES.2022.27.24.2200455","article-title":"Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022","volume":"27","author":"S Pleininger","year":"2022","journal-title":"Euro Surveill"},{"issue":"27","key":"pone.0340486.ref019","first-page":"1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"DW Eyre","year":"2018","journal-title":"Euro Surveill"},{"issue":"2","key":"pone.0340486.ref020","article-title":"High prevalence of ceftriaxone-resistant and XDR Neisseria gonorrhoeae in several cities of Cambodia, 2022-23: WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)","volume":"6","author":"V Ouk","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"pone.0340486.ref021","unstructured":"World Health Organization. Multi-Drug Resistant Gonorrhoea Fact Sheet. [Cited 2023 August 1]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multi-drug-resistant-gonorrhoea"},{"issue":"3","key":"pone.0340486.ref022","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/QCO.0000000000000058","article-title":"Preparing for an era of untreatable gonorrhea","volume":"27","author":"LA Barbee","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"pone.0340486.ref023","unstructured":"Multi-drug resistant gonorrhoea. [Cited 2025 October 25]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multi-drug-resistant-gonorrhoea"},{"key":"pone.0340486.ref024","volume-title":"WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","year":"2024"},{"key":"pone.0340486.ref025","unstructured":"Chlamydial Infections - STI Treatment Guidelines. 2022. [Cited 2025 September 21]. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/chlamydia.htm"},{"issue":"11","key":"pone.0340486.ref026","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3390\/antibiotics11111634","article-title":"Therapeutic Options for Chlamydia trachomatis infection: present and future","volume":"11","author":"R Rodrigues","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"pone.0340486.ref027","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jac\/dkx392","article-title":"Chlamydia trachomatis antimicrobial susceptibility in colorectal and endocervical cells","volume":"73","author":"C Foschi","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"pone.0340486.ref028","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/cid\/ciab153","article-title":"Doxycycline versus azithromycin for the treatment of rectal chlamydia in men who have sex with men: a randomized controlled trial","volume":"73","author":"JC Dombrowski","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0340486.ref029","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1258\/095646203321156872","article-title":"Co-infection with gonorrhoea and chlamydia: how much is there and what does it mean?","volume":"14","author":"S Creighton","year":"2003","journal-title":"Int J STD AIDS"},{"issue":"3","key":"pone.0340486.ref030","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04500-22","article-title":"Neisseria gonorrhoeae Coinfection during Chlamydia muridarum Genital Latency Does Not Modulate Murine Vaginal Bacterial Shedding","volume":"11","author":"D Onorini","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"4","key":"pone.0340486.ref031","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1128\/IAI.01155-10","article-title":"Chlamydial infection increases gonococcal colonization in a novel murine coinfection model","volume":"79","author":"RA Vonck","year":"2011","journal-title":"Infect Immun"},{"issue":"10","key":"pone.0340486.ref032","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"H Xue","year":"2018","journal-title":"Int J Biol Sci"},{"issue":"3","key":"pone.0340486.ref033","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/apm.13014","article-title":"The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs","volume":"128","author":"S Foerster","year":"2020","journal-title":"APMIS"},{"issue":"6","key":"pone.0340486.ref034","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"A Ben Salah","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0340486.ref035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and drug administration approval of ambisome (liposomal amphotericin b) for treatment of visceral leishmaniasis","volume":"28","author":"A Meyerhoff","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0340486.ref036","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-015-0980-0","article-title":"Tetracyclines in malaria","volume":"14","author":"T Gaillard","year":"2015","journal-title":"Malar J"},{"key":"pone.0340486.ref037","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S30139","article-title":"Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)","volume":"8","author":"V Wiwanitkit","year":"2012","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"pone.0340486.ref038","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.05013-11","article-title":"Epidemiology of and diagnostic strategies for toxoplasmosis","volume":"25","author":"F Robert-Gangneux","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"pone.0340486.ref039","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14756366.2021.1991336","article-title":"Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae","volume":"37","author":"NS Abutaleb","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"6","key":"pone.0340486.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325722","article-title":"A novel peptide mimetic, brilacidin, for combating multidrug-resistant Neisseria gonorrhoeae","volume":"20","author":"AS Abdelsattar","year":"2025","journal-title":"PLoS One"},{"issue":"11","key":"pone.0340486.ref041","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1021\/acs.jmedchem.4c00740","article-title":"Development of penicillin-based carbonic anhydrase inhibitors targeting multidrug-resistant neisseria gonorrhoeae","volume":"67","author":"A Bonardi","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"pone.0340486.ref042","doi-asserted-by":"crossref","first-page":"14468","DOI":"10.1038\/s41598-023-41442-5","article-title":"Substituted salicylic acid analogs offer improved potency against multidrug-resistant Neisseria gonorrhoeae and good selectivity against commensal vaginal bacteria","volume":"13","author":"H Almolhim","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0340486.ref043","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1038\/s41598-020-62696-3","article-title":"Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae","volume":"10","author":"A Elkashif","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0340486.ref044","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms22052427","article-title":"N-(1,3,4-Oxadiazol-2-yl) Benzamides as antibacterial agents against neisseria gonorrhoeae","volume":"22","author":"GA Naclerio","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0340486.ref045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1021\/acsinfecdis.1c00553","article-title":"In Vitro and In Vivo activity of (Trifluoromethyl)pyridines as Anti-Chlamydia trachomatis Agents","volume":"8","author":"MA Seleem","year":"2022","journal-title":"ACS Infect Dis"},{"issue":"2","key":"pone.0340486.ref046","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00339-23","article-title":"Metabolic dormancy in Chlamydia trachomatis treated with different antibiotics","volume":"92","author":"DD Rockey","year":"2024","journal-title":"Infect Immun"},{"issue":"24","key":"pone.0340486.ref047","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.2174\/15680266113136660219","article-title":"Native brazilian plants against nosocomial infections: a critical review on their potential and the antimicrobial methodology","volume":"13","author":"P H. Moreno","year":"2013","journal-title":"CTMC"},{"issue":"2","key":"pone.0340486.ref048","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1574-6976.2007.00095.x","article-title":"Penicillin-binding proteins and beta-lactam resistance","volume":"32","author":"A Zapun","year":"2008","journal-title":"FEMS Microbiol Rev"},{"issue":"7","key":"pone.0340486.ref049","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1128\/AAC.00326-12","article-title":"In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?","volume":"56","author":"M Unemo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0340486.ref050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14787210.2025.2505559","article-title":"An overview of potential combination therapies with ceftriaxone as a treatment for gonorrhoea","volume":"23","author":"I Kanesaka","year":"2025","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"pone.0340486.ref051","first-page":"1207","article-title":"The Beta lactam antibiotics as an empirical therapy in a developing country: an update on their current status and recommendations to counter the resistance against them","volume":"7","author":"B Thakuria","year":"2013","journal-title":"J Clin Diagn Res"},{"issue":"2","key":"pone.0340486.ref052","doi-asserted-by":"crossref","first-page":"147","DOI":"10.7164\/antibiotics.36.147","article-title":"Synthesis and antibacterial activity of asparagine derivatives of aminobenzylpenicillin","volume":"36","author":"M Wagatsuma","year":"1983","journal-title":"J Antibiot"},{"key":"pone.0340486.ref053","unstructured":"Medicine C. Extralabel Use and Antimicrobials. 2024. [Cited 2025 September 14]. https:\/\/www.fda.gov\/animal-veterinary\/antimicrobial-resistance\/extralabel-use-and-antimicrobials"},{"issue":"1","key":"pone.0340486.ref054","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3201\/eid1601.090729","article-title":"Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada","volume":"16","author":"L Dutil","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"pone.0340486.ref055","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.tibs.2018.06.011","article-title":"How macrolide antibiotics work","volume":"43","author":"N V\u00e1zquez-Laslop","year":"2018","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"pone.0340486.ref056","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a027110","article-title":"Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance","volume":"7","author":"S Paukner","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"pone.0340486.ref057","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1128\/AAC.42.11.2985","article-title":"Purification and characterization of virginiamycin M1 reductase from streptomyces virginiae","volume":"42","author":"N Suzuki","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0340486.ref058","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1128\/AAC.50.4.1458-1462.2006","article-title":"Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center","volume":"50","author":"KS Long","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0340486.ref059","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2958.2001.02595.x","article-title":"The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome","volume":"41","author":"SM Poulsen","year":"2001","journal-title":"Mol Microbiol"},{"issue":"11","key":"pone.0340486.ref060","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01497-17","article-title":"In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant neisseria gonorrhoeae","volume":"61","author":"S Jacobsson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0340486.ref061","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1128\/AAC.48.4.1347-1349.2004","article-title":"Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides","volume":"48","author":"OY Misyurina","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0340486.ref062","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01346-24","article-title":"In vitro test of the novel antibiotic lefamulin alone and in combination with doxycycline against Mycoplasma genitalium","volume":"69","author":"K Salado-Rasmussen","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0340486.ref063","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02380-17","article-title":"In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens","volume":"62","author":"S Paukner","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0340486.ref064","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.mcna.2023.08.015","article-title":"The management of gonorrhea in the era of emerging antimicrobial resistance: what primary care clinicians should know","volume":"108","author":"LAS Quilter","year":"2024","journal-title":"Med Clin North Am"},{"key":"pone.0340486.ref065","unstructured":"CDC. Antibiotic Resistance Threats Report. 2019. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html"},{"key":"pone.0340486.ref066"},{"issue":"1","key":"pone.0340486.ref067","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.jepm.2013.11.005","article-title":"Advances in avian clinical therapeutics","volume":"23","author":"D Sanchez-Migallon Guzman","year":"2014","journal-title":"Journal of Exotic Pet Medicine"},{"issue":"8","key":"pone.0340486.ref068","first-page":"2156","article-title":"Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital","volume":"75","author":"YD Bakthavatchalam","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"pone.0340486.ref069","article-title":"Efficacy and safety of oral and IV levonadifloxacin therapy in management of bacterial infections: findings of a prospective, observational, multi-center, post-marketing surveillance study","volume":"16","author":"S Saseedharan","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"pone.0340486.ref070","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/lam.13494","article-title":"Impact of ciprofloxacin impurities on bacterial growth, antibiotic resistance development and content assays","volume":"73","author":"C Ching","year":"2021","journal-title":"Lett Appl Microbiol"},{"issue":"1","key":"pone.0340486.ref071","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00972-23","article-title":"High-level nitrofurantoin resistance in a clinical isolate of Klebsiella pneumoniae: a comparative genomics and metabolomics analysis","volume":"9","author":"M Hussein","year":"2024","journal-title":"mSystems"},{"key":"pone.0340486.ref072","doi-asserted-by":"crossref","first-page":"1055929","DOI":"10.3389\/fcimb.2022.1055929","article-title":"Nigericin is effective against multidrug resistant gram-positive bacteria, persisters, and biofilms","volume":"12","author":"X Zhu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"pone.0340486.ref073","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/BF02532337","article-title":"Nigericin-induced Na+\/H+ and K+\/H+ exchange in synaptosomes: effect on [3H]GABA release","volume":"21","author":"R Rodr\u00edguez","year":"1996","journal-title":"Neurochem Res"},{"issue":"8","key":"pone.0340486.ref074","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41429-023-00629-8","article-title":"Antibiotics in the clinical pipeline as of December 2022","volume":"76","author":"MS Butler","year":"2023","journal-title":"J Antibiot (Tokyo)"},{"issue":"6","key":"pone.0340486.ref075","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acsinfecdis.0c00025","article-title":"Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria","volume":"6","author":"SS Stokes","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"11","key":"pone.0340486.ref076","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"AK Talley","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0340486.ref077","unstructured":"Jiang XY. The purposes and antibacterials of a kind of multi-arm AIE molecule in preparation antibacterials. 2019. https:\/\/patents.google.com\/patent\/CN110123801A\/en?oq=CN110123801A"},{"issue":"3","key":"pone.0340486.ref078","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/ja.2010.4","article-title":"Novel antibacterial compounds specifically targeting the essential WalR response regulator","volume":"63","author":"Y Gotoh","year":"2010","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"pone.0340486.ref079","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0304-4017(80)90048-5","article-title":"Serological responses to bovine anaplasmosis following treatment with gloxazone","volume":"7","author":"N McHardy","year":"1980","journal-title":"Veterinary Parasitology"},{"issue":"1","key":"pone.0340486.ref080","article-title":"Neisseria gonorrhoeae drives Chlamydia trachomatis into a persistence-like state during in vitro co-infection","volume":"92","author":"LM Ball","year":"2024","journal-title":"Infect Immun"},{"issue":"2","key":"pone.0340486.ref081","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2021.03.005","article-title":"EVO100 prevents chlamydia and gonorrhea in women at high risk of infection","volume":"225","author":"BT Chappell","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"7938","key":"pone.0340486.ref082","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/d41586-022-03801-6","article-title":"Push to use antibiotics to prevent sexually transmitted infections raises concerns","volume":"612","author":"D Lewis","year":"2022","journal-title":"Nature"},{"issue":"3","key":"pone.0340486.ref083","first-page":"553","article-title":"Doxycycline in the management of sexually transmitted infections","volume":"73","author":"H Peyriere","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"pone.0340486.ref084","doi-asserted-by":"crossref","first-page":"116502","DOI":"10.1016\/j.bcp.2024.116502","article-title":"Walrycin B, as a novel separase inhibitor, exerts potent anticancer efficacy in a mouse xenograft model","volume":"229","author":"Q Zhu","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"pone.0340486.ref085","doi-asserted-by":"crossref","first-page":"111262","DOI":"10.1016\/j.biopha.2021.111262","article-title":"Evidence of nigericin as a potential therapeutic candidate for cancers: A review","volume":"137","author":"G Gao","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"pone.0340486.ref086","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01445-25","article-title":"Repurposing epetraborole to combat Neisseria gonorrhoeae and Chlamydia trachomatis infections","volume":"70","author":"AS Abdelsattar","year":"2026","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:22:30Z","timestamp":1770402150000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340486"}},"subtitle":[],"editor":[{"given":"Yung-Fu","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":86,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340486","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}